MNK6106

Mallinckrodt · Phase 2 active Small molecule

At a glance

Generic name	MNK6106
Also known as	Study Drug, L-Ornithine Phenylacetate
Sponsor	Mallinckrodt
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MNK6106 CI brief — competitive landscape report
MNK6106 updates RSS · CI watch RSS
Mallinckrodt portfolio CI